Showing 411-420 of 1780 results for "".
How to Market Seven Top Skincare Trends for 2022
https://reachmd.com/topics/skincare/how-to-market-seven-top-skincare-trends-for-2022/35137/Grow your practice with digital strategies centered on top trendsReimagining Menopause with Hormones and Longevity
https://reachmd.com/ma-issues-index/jan-feb-2026-issue/reimagining-menopause-with-hormones-and-longevity/54435/Innovations in Less-Invasive Epilepsy Surgery
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/innovations-in-less-invasive-epilepsy-surgery/39963/Recent developments in epilepsy surgery underscore a growing trend toward reduced invasiveness and expanded clinical indications.Using Nerve Blocks to Avoid Pain and Narcotics for Rhinoplasty
https://reachmd.com/topics/surgical/using-nerve-blocks-to-avoid-pain-and-narcotics-for-rhinoplasty/35422/A Q&A with Anil R. Shah, MD, FACSA Holistic Approach to Skincare: Partnering with the Aesthetic Patient
https://reachmd.com/ma-supplements/2022-mar-apr-insert/a-holistic-approach-to-skincare-partnering-with-the-aesthetic-patient/35158/Beyond offering patients the latest innovative treatments, aesthetic physicians stress the importance of caring for patients’ overall skin healthStudy Shows Affordable, OTC SkinCare Offers Benefits After Noninvasive Aesthetic Procedures
https://reachmd.com/ma-issues-index/march-april-2026-issue/study-shows-affordable-otc-skincare-offers-benefits-after-noninvasive-aesthetic-procedures/56637/Topical solutions to boost tolerability of in-office treatmentsGFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
https://reachmd.com/programs/neurofrontiers/gfap-and-vegf-trajectories-in-adult-type-3-spinal-muscular-atrophy-under-nusinersen/54637/Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
https://reachmd.com/programs/heart-matters/heart-failure-mortality-cardiac-amyloidosis/49064/Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
https://reachmd.com/clinical-practice/cardiology/sotagliflozin-in-hfpef-without-diabetes-inside-the-sota-p-cardia-trial-from-aha-2025/39898/SOTA-P-CARDIA shows sotagliflozin improves LV mass, exercise capacity, and quality of life in non-diabetic HFpEF, supporting dual SGLT1/2 inhibition.Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
https://reachmd.com/clinical-practice/cardiology/targeting-epicardial-adipose-tissue-in-patients-with-hfpef-without-diabetes-sotagliflozin-effect-from-sota-p-cardia-trial-sub-analysis/49274/Review SOTA-P-CARDIA sub-analysis findings on the effects of sotagliflozin on epicardial adipose tissue in patients with HFpEF without diabetes.